Form 4: Curis Inc. CDO Jonathan B. Zung Reports Stock Option Grant
SEC Form 4 Filing
Jonathan B. Zung, Chief Development Officer of Curis Inc., reports the acquisition of a stock option grant for 135,000 shares of common stock.
Summary
- On May 20, 2025, Jonathan B. Zung, the Chief Development Officer (CDO) of Curis Inc., reported a transaction involving derivative securities.
- Zung acquired an employee stock option (right to buy) 135,000 shares of Curis Inc. common stock at an exercise price of $3.13 per share.
- The option grant was initially approved by the Board of Directors on January 28, 2025, contingent upon shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan.
- Shareholder approval was obtained on May 20, 2025, at the annual meeting.
- The options vest as to 25% of the original shares on January 28, 2026, and then an additional 6.25% each successive quarter until January 28, 2029.
- Following the reported transaction, Zung beneficially owns 135,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. The vesting schedule promotes long-term alignment.
Positives
- The grant of stock options to a key executive aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CDO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are typically benchmarked against peer companies in the biotechnology sector to attract and retain talent.
- The vesting schedule and exercise price are standard features of stock option plans, designed to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the option grant positively as it aligns management's interests with the company's long-term success.
- Employees may see the option grant as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| January 28, 2025 | Board of Directors approved the option grant, contingent on shareholder approval. |
| May 20, 2025 | Shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan at the 2025 annual meeting. |
| May 20, 2025 | Date of the reported transaction (option grant). |
| May 22, 2025 | Date of the Form 4 filing. |
| January 28, 2026 | First vesting date for 25% of the option shares. |
| January 28, 2029 | Final vesting date for the option shares. |
| January 27, 2035 | Expiration date of the options. |
Keywords
stock option, Form 4, Curis Inc, Zung, derivative securities, beneficial ownership, officer, CRIS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.